Kevin Tang, Director at Aurinia Pharmaceuticals Inc. (AUPH), bought 900,000 shares at $13.90 ($12.7M) on 2026-02-27, disclosed to the SEC on 2026-03-03.
Open-market purchase of $12.7M AUPH by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.90 | 300,000 | $4.2M | 32.9% |
| 2 | $14.12 | 214,839 | $3.0M | 23.9% |
| 3 | $14.38 | 1,600 | $23K | 0.2% |
| 4 | $14.21 | 115,792 | $1.6M | 13.0% |
| 5 | $14.33 | 83,561 | $1.2M | 9.4% |
| 6 | $14.22 | 184,208 |
| $2.6M |
| 20.6% |
| Total | $14.10 avg | 900,000 | $12.7M | 100% |
| Filing → |
| FULC | BUY | 2026-07-20 | $595K | — | Filing → |
| BOLD | BUY | 2026-07-16 | $156K | — | Filing → |
| FULC | BUY | 2026-07-15 | $891K | — | Filing → |